clinical trial · NCT07419334
Study of ALK-001 on the Progression of Stargardt Disease
Alkeus Pharmaceuticals, Inc.·phase3·recruiting·n = 230
Stargardt DiseaseALK-001Placebo
brief summary
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
started
Apr 1, 2026
primary completion
Oct 1, 2029
completion
Dec 1, 2030
last updated
Apr 9, 2026
official title
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK 001) on the Progression of Stargardt Disease (STGD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol